Aim high - Adjuvant interferon in melanoma (high risk): No confirmation yet that low dose interferon is of benefit

Míreanna comhchosúla

• Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
  de réir: Hancock, B, et al.
  Foilsithe / Cruthaithe: (2004)
• Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
  de réir: Mia Salans, et al.
  Foilsithe / Cruthaithe: (2021-10-01)
• Adjuvant therapy of melanoma with interferon: lessons of the past decade
  de réir: Kirkwood John M, et al.
  Foilsithe / Cruthaithe: (2008-10-01)
• Pembrolizumab Versus High-Dose Interferon-α2b as Adjuvant Therapy for Pediatric Melanoma: A Retrospective Study
  de réir: Yu Du, et al.
  Foilsithe / Cruthaithe: (2024-01-01)
• Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients
  de réir: Kirkwood John M, et al.
  Foilsithe / Cruthaithe: (2011-05-01)